{"id":814918,"date":"2025-02-19T09:17:14","date_gmt":"2025-02-19T14:17:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"modified":"2025-02-19T09:17:14","modified_gmt":"2025-02-19T14:17:14","slug":"palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","title":{"rendered":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference"},"content":{"rendered":"
\n

\n
\n
\n On-demand video webcast now available here<\/u>
\n <\/em>
\n <\/a>
\n
\n \u00a0<\/u>
\n <\/em>\n <\/p>\n

\n Carlsbad,\u00a0CA, Feb. 19, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n
\n Palisade Bio, Inc.\u00a0<\/u>
\n <\/a>(Nasdaq: PALI) (\u201cPalisade\u201d, \u201cPalisade Bio\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor “Top 5 for \u201825\u201d On-Demand Conference<\/u><\/a>.<\/p>\n

As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.\u00a0<\/p>\n

The on-demand video webcast is now accessible for viewing here<\/u><\/a> and on the Events<\/u><\/a> page in the Investors and News<\/u><\/a> section of the Company\u2019s website (<\/u>palisadebio.com<\/u><\/a>).<\/u><\/p>\n

\n About Palisade Bio\u00a0<\/strong>\n <\/p>\n

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to\u00a0www.palisadebio.com<\/u><\/a>.<\/u><\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the safety and tolerability, PK and drug release characteristics of PALI-2108 based on the Company\u2019s preclinical studies and preliminary data from the SAD portion of the Company\u2019s Phase 1b\/2a clinical study, indications and anticipated benefits of PALI-2108 and the expected timing of the release of topline data from the Phase 1b\/2a clinical study. These forward-looking statements are based on the Company\u2019s current expectations. Forward-looking statements involve risks and uncertainties. The Company\u2019s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company is heavily dependent on the success of PALI-2108, which is in the early stages of clinical development and may not successfully progress through clinical development or receive regulatory approval; preliminary clinical study results or the results from earlier preclinical studies may not be predictive of final or future results and unexpected adverse side effects or inadequate efficacy of PALI-2108 may limit its development, regulatory approval and\/or commercialization; the Company needs to raise significant additional funds to support its operations and the continued development of PALI-2108; the timing and outcome of the Company\u2019s current and anticipated clinical studies related to its product candidates; indications of use and estimates about the size and growth potential of the markets for the Company\u2019s product candidates, and its ability to serve those markets, including any potential revenue generated; the Company\u2019s ability to maintain the Nasdaq listing of its securities; the Company\u2019s ability to compete effectively in a competitive industry; the Company\u2019s ability to identify and qualify manufacturers to provide API and manufacture drug product; the Company\u2019s ability to enter into commercial supply agreements; the Company\u2019s ability to attract and retain key scientific or management personnel; the accuracy of the Company\u2019s estimates regarding expenses, future revenues, capital requirements and needs for additional financing; and the impact of any global event on the Company\u2019s business, and operations, and supply. Additional risks and uncertainties can be found in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 26, 2024, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.<\/p>\n

\n Investor Relations Contact<\/strong>
\n
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

On-demand video webcast now available here \u00a0 Carlsbad,\u00a0CA, Feb. 19, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc.\u00a0 (Nasdaq: PALI) (\u201cPalisade\u201d, \u201cPalisade Bio\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor “Top 5 for \u201825\u201d On-Demand Conference. As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.\u00a0 The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors and News section of the Company\u2019s website … <\/p>\n

Continue reading “Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-814918","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPalisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"On-demand video webcast now available here \u00a0 Carlsbad,\u00a0CA, Feb. 19, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc.\u00a0 (Nasdaq: PALI) (\u201cPalisade\u201d, \u201cPalisade Bio\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor “Top 5 for \u201825\u201d On-Demand Conference. As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.\u00a0 The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors and News section of the Company\u2019s website … Continue reading "Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-19T14:17:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\",\"datePublished\":\"2025-02-19T14:17:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"},\"wordCount\":702,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\",\"name\":\"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==\",\"datePublished\":\"2025-02-19T14:17:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","og_description":"On-demand video webcast now available here \u00a0 Carlsbad,\u00a0CA, Feb. 19, 2025 (GLOBE NEWSWIRE) — Palisade Bio, Inc.\u00a0 (Nasdaq: PALI) (\u201cPalisade\u201d, \u201cPalisade Bio\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it participated in the Virtual Investor “Top 5 for \u201825\u201d On-Demand Conference. As part of the event, JD Finley, Chief Executive Officer of Palisade Bio, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to the Company in 2025.\u00a0 The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors and News section of the Company\u2019s website … Continue reading \"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-19T14:17:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference","datePublished":"2025-02-19T14:17:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"},"wordCount":702,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/","name":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==","datePublished":"2025-02-19T14:17:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDcwNCM2NzU3MTY5IzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio, Inc. Participates in the Virtual Investor \u201cTop 5 for \u201825\u201d On-Demand Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=814918"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/814918\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=814918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=814918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=814918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}